The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures to support the development of innovative drugs within the city. The initiative aims to stimulate biopharmaceutical companies’ innovative development by ensuring improved access to novel drugs and devices in clinical settings.
- Promoting Hospital Access to Innovative Medical Products:
The Guangzhou government is committed to establishing a dedicated green channel for the online procurement of innovative drugs, enhancing the rapid online procurement mechanism, and streamlining the online procurement process. Except for drugs and devices under national price negotiation and volume-based procurement (VBP), procurement prices for other drugs can be independently negotiated between developers and medical institutions. The city will also encourage designated medical institutions to hold pharmaceutical meetings and promptly include nationally negotiated drugs and innovative medical devices in their procurement scope. - Greater Clinical Application of Novel Drugs:
The government will not impose budget ceiling caps on medical institutions. The cost of innovative drugs such as nationally negotiated drugs incurred by designated medical institutions will be settled separately or included in the Diagnosis-Intervention Packet (DIP) as a bonus. The DIP special case negotiation mechanism will be optimized, and applications for special case payments for cases using innovative drugs and medical technologies will be supported. Designated medical institutions will be supported to include “dual channel” drugs in both the hospital drug catalog and external prescription drug catalog. - Expand Novel Drug Payment Channels:
The government will promote the application of the electronic prescription circulation platform and optimize the online full process of drug purchase and medical insurance settlement services. For innovative drugs like national negotiated drugs, separate payment management will be implemented, increasing the medical insurance reimbursement proportion without a payment limit, similar to special disease treatments in general outpatient clinics and outpatient clinics. The “Suisuikang” pilot program, the province’s commercial supplementary health insurance, will be deepened, including self-funded drugs in medical insurance payment according to regulations without limiting disease types and varieties. Eligible national negotiated drugs and innovative drugs will be given preferential treatment, and pharmaceutical enterprises that meet the conditions for innovative drugs will be supported to apply for inclusion in the “Suisuikang” handling agency at any time. - Ratchet up Support for Innovative Medical Services:
The government will support enterprises in negotiating the national basic medical insurance drug list, actively seek policy support from relevant national and provincial departments, and provide more support for innovative pharmaceutical equipment. Regular “Medical Insurance Hospitals Enterprises” exchange meetings on the implementation and use of national negotiated drugs will be held to promote their use in hospitals.- Flcube.com
